title: Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa.
abstract: Osteoporosis is a known consequence of anorexia nervosa (AN) in adults, but the mechanism of bone loss is not established, and there have been no studies of bone mass in women developing AN before attaining peak bone mass. To investigate the causes of bone loss in AN and to determine the consequences of developing AN during adolescence on bone mass, we compared the effects of AN on cortical and trabecular bone in 26 women with AN (19 adults, 18-42 yr old, and 7 adolescents, 14.9-17.0 yr old) using direct radial photon absorptiometry and both single and dual energy spinal computed tomography. The adult AN patients had marked spinal osteopenia [mean bone density, 120 +/- 28 (+/- SD) mg K2HPO4/cm3] compared with age-matched normal women (mean, 176 +/- 26 mg K2HPO4/cm3; P = 0.0001), which was severe (greater than 2 SD below the normal mean) in 50% of patients. Adult AN patients with the onset of amenorrhea before age 18 yr had significantly (P = 0.04) lower spinal bone density than those developing amenorrhea later (mean, 103 +/- 25 vs. 129 +/- 25 mg K2HPO4/cm3) independent of other variables correlated with bone density (duration of amenorrhea or urinary cortisol excretion). We found a negative correlation between spinal bone density and duration of amenorrhea (P = 0.006; r = -0.53). To determine the contribution of endogenous cortisol excess to the pathogenesis of the osteoporosis, urinary cortisol was measured. Urinary cortisol/creatinine clearance was significantly (P = 0.001) higher in AN patients than in normal women (mean, 2.7 +/- 1.2 vs. 1.0 +/- 0.3 nmol/L) and was negatively correlated (P = 0.03; r = -0.43) with bone mass. We conclude that AN affects trabecular bone and that both the onset of AN before attainment of peak bone mass and prolonged duration of amenorrhea result in more severe osteopenia. In addition to the significant contribution of hypogonadism, the cortisol excess that occurs in AN patients may contribute to the development of osteoporosis in these patients.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Boston 02114.
authors.forename: B M
authors.initials: BM
authors.lastname: Biller
authors.forename: V
authors.initials: V
authors.lastname: Saxe
authors.forename: D B
authors.initials: DB
authors.lastname: Herzog
authors.forename: D I
authors.initials: DI
authors.lastname: Rosenthal
authors.forename: S
authors.initials: S
authors.lastname: Holzman
authors.forename: A
authors.initials: A
authors.lastname: Klibanski
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000378:metabolism; D000856:Anorexia Nervosa / Q000150:complications* / Q000378:metabolism; D001842:Bone and Bones / Q000032:analysis / Q000378:metabolism; D002117:Calcitriol / Q000032:analysis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000032:analysis; D013006:Growth Hormone / Q000032:analysis; D006801:Humans; D006854:Hydrocortisone / Q000032:analysis / Q000378:metabolism / Q000502:physiology; D007986:Luteinizing Hormone / Q000032:analysis; D010024:Osteoporosis / Q000209:etiology* / Q000378:metabolism; D011388:Prolactin / Q000032:analysis; D013002:Somatomedins / Q000032:analysis; D013739:Testosterone / Q000032:analysis
chemical_list: D013002:Somatomedins; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D002117:Calcitriol; D006854:Hydrocortisone